Skip to end of metadata
Go to start of metadata


MITRE and the  HL7® FHIR® Accelerator CodeX Community invite you to a unique MITRE Listening Session on oncology clinical pathways and prior authorization of cancer therapies on June 26, 2020 from 10:00-11:30 EDT. 

Oncology is a dynamic specialty with a rapid expansion of new therapies and tumor genomics.  Over the past five years the use of oncology clinical pathways became a standard approach to assist oncologists in treatment recommendations.  Oncology clinical pathways can facilitate prior authorization for cancer treatments through interaction with payers using evidence-based treatment recommendations.  

The session will include three 15-minute presentations, each from a different stakeholder: health system, payer, and pathway vendor.  The focus of the presentations will be on the experiences, challenges, and opportunities of each stakeholder.  There will be opportunity for discussion at the end of the session. 

Register in advance for this meeting: 

https://mitre.zoomgov.com/meeting/register/vJItdOCtqDMjHf9HtHV-I6ZnIjEyp_KpsVs    

After registering, you will receive a confirmation email containing information about joining the meeting.  

AGENDA  

Oncology Clinical Pathways and Prior Authorization Listening Session  

June 26, 2020 

Time 10 – 11 am ET  

Note: additional discussion time reserved from 11:00 – 11:30 ET 

  • Introduction 
    • CodeX – Steve Bratt, PhD, FHIR CodeX Accelerator Lead, MITRE 
    • 5 minutes to set the stage for the listening session
  • Health system perspective
    • Larry Shulman, MD/Peter Gabriel, MD, MSE  
    • University of Pennsylvania Cancer Center 
    • 15-minute presentation
  • Payer perspective
    • Melanie Combs-Dyer  
    • Director of Innovation, Mettle Solutions LLC 
    • 15-minute presentation
  • Pathways vendor perspective 
    • Tyler Haydell  
    • Senior Product Manager  
    • Flatiron Health 
    • 15-minute presentation

Discussion / Q&A

  • 40 minutes
  • No labels